# Scibase Holding > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/scibaseholding). ## Overview SciBase Holding AB is a Swedish medical technology group focused on dermatology diagnostics and early detection of skin disease. The company develops and commercializes Nevisense, a point-of-care platform that combines electrical impedance spectroscopy and AI to support clinicians in assessing suspicious skin lesions and related skin-barrier applications. ## Products & services • Nevisense dermatology diagnostic platform • Nevisense Go handheld instrument • EIS-based skin lesion assessment • Clinical and regulatory commercialization support • Product development for new dermatology indications - **Diagnostic devices** (70%) — Point-of-care instruments and systems used to assess skin lesions and skin-barrier conditions. - **Disposable electrodes and consumables** (20%) — Single-use components required to run the Nevisense diagnostic workflow. - **Software and AI-enabled analysis** (5%) — Algorithmic and software elements that support diagnostic interpretation. - **Services and collaboration revenue** (5%) — Commercial and development-related activities tied to partners and market access. - Nevisense dermatology diagnostic platform - Nevisense Go handheld instrument - EIS-based skin lesion assessment - Clinical and regulatory commercialization support - Product development for new dermatology indications ## Customers SciBase sells primarily to dermatologists, skin cancer clinics, and other clinicians who evaluate suspicious lesions and need objective support in diagnosis. The company also works with research and development partners for new applications in dermatology and skin-barrier assessment. Demand is driven by clinical accuracy, workflow fit, and reimbursement or guideline adoption. - **Dermatology clinics** (primary) — Buy Nevisense to support evaluation of suspicious skin lesions and improve diagnostic confidence. - **Skin cancer centers** (primary) — Use the platform in workflows focused on melanoma and nonmelanoma skin cancer detection. - **Research and collaboration partners** (secondary) — Work with SciBase on new indications such as atopic dermatitis and skin-barrier applications. - **Hospitals and outpatient specialists** (secondary) — Adopt the device where point-of-care dermatology diagnostics can fit existing clinical pathways. - Dermatologists using Nevisense for lesion assessment - Skin cancer clinics seeking objective diagnostic support - Hospitals and outpatient centers with dermatology workflows - Research partners evaluating new dermatology indications - Clinicians adopting tools that improve diagnostic confidence ## Geography SciBase is headquartered in Stockholm and operates through a Swedish parent company with subsidiaries in the United States and Germany. The business is international in scope, with commercialization tied to regulated markets such as the U.S., EU, and Australia, and with foreign-currency exposure mainly in EUR and, over time, USD. - Headquartered in Stockholm, Sweden - U.S. subsidiary supports American sales and marketing - German subsidiary supports a key European market - Commercialization spans regulated markets in the U.S. and EU - Foreign-currency exposure is mainly EUR, with growing USD exposure ## Strategy SciBase’s strategy is centered on expanding clinical adoption of Nevisense and extending the platform into additional dermatology and skin-barrier indications. The company also emphasizes regulatory approvals, reimbursement access, and partnerships that can broaden market reach and support commercialization. - **Broaden clinical and geographic commercialization** (medium-term) — The platform needs wider adoption to scale beyond niche use and support recurring demand. - **Expand indications and product utility** (medium-term) — New clinical uses can increase the addressable market and improve platform relevance. - **Secure reimbursement and guideline support** (long-term) — Clinical adoption is easier when the method is recognized in reimbursement systems and guidelines. - **Improve manufacturing and supply-chain robustness** (short-term) — Disposable electrodes and components must be available reliably for clinical use and scaling. - Expand adoption of Nevisense in dermatology workflows - Develop new indications beyond melanoma detection - Pursue reimbursement and guideline inclusion - Use partnerships to accelerate market access - Strengthen supply chain and product design for scalability ## Risks SciBase faces commercialization risk because its products depend on regulatory approval, reimbursement, and clinician adoption in a specialized medical market. The company is also exposed to foreign-exchange volatility, supply-chain disruption, and dependence on key personnel and external partners. As a medical technology business, product performance, quality, and compliance are central to both market access and long-term credibility. - **Commercialization and market adoption risk** [high] — Revenue depends on clinicians adopting Nevisense and on successful launches of new applications. - **Reimbursement and guideline risk** [high] — Without reimbursement or clinical guideline inclusion, adoption can remain limited. - **Foreign exchange risk** [medium] — The group reports in SEK but has exposure to EUR and future USD cash flows and balances. - **Supply-chain and component availability risk** [high] — Electronic components and supplies are needed to manufacture and deliver devices and electrodes. - **Key-person dependence** [medium] — The company relies on experienced personnel with product, partner, and market knowledge. - Commercialization may be slower than expected in new markets - Reimbursement and guideline adoption may remain limited - EUR and USD swings can affect reported results - Component shortages can disrupt manufacturing and deliveries - Key-person dependence is material in a small medtech business ## Accounting SciBase’s reporting is shaped by estimates around foreign-currency translation, lease liabilities, and the valuation of group-company investments and intragroup balances. As a development-stage medtech company, judgment around capitalization, impairment, and the timing of commercialization-related costs can also affect reported results and equity. - **Foreign currency translation** — Affects reported equity, profit, and comparability across periods - **Lease accounting under IFRS 16** — Changes leverage metrics and operating expense profile - **Impairment of subsidiary investments** — Can materially affect parent-company equity and profit - **Estimates around commercialization costs and product development** — Affects operating loss timing and period-to-period comparability - Foreign subsidiaries are translated into SEK, affecting equity and earnings - EUR and USD exchange rates can move reported results and balance-sheet values - IFRS 16 lease accounting affects reported liabilities and operating costs - Impairment of shares in subsidiaries can materially affect parent-company equity - Commercialization-stage spending and development judgments affect comparability --- *Last updated: 2026-08-11T04:04:55.688510+00:00*